Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine

被引:86
作者
Kwentus, Joseph [1 ]
Riesenberg, Robert A. [2 ]
Marandi, Morteza [3 ]
Manning, Raymond A. [4 ]
Allen, Michael H. [5 ]
Fishman, Robert S. [6 ]
Spyker, Daniel A. [6 ]
Kehne, John H. [7 ]
Cassella, James V. [6 ]
机构
[1] Precise Res Ctr, Flowood, MS 39232 USA
[2] Atlanta Ctr Med Res, Atlanta, GA USA
[3] Comprehens Neurosci Inc, Cerritos, CA USA
[4] CNRI Los Angeles LLC, Pico Rivera, CA USA
[5] Univ Colorado, Colorado Depress Ctr, Aurora, CO USA
[6] Alexza Pharmaceut Inc, Mountain View, CA USA
[7] Translat Neuropharmacol Consulting LLC, Potomac, MD USA
关键词
agitation; bipolar I disorder; clinical trial; inhaled loxapine; loxapine; placebo-controlled; randomized; rapid acute treatment; Staccato (R); DOUBLE-BLIND; INTRAMUSCULAR OLANZAPINE; PHARMACOLOGICAL MANAGEMENT; HALOPERIDOL; PHARMACOTHERAPY; MEDICATIONS; EFFICACY;
D O I
10.1111/j.1399-5618.2011.00975.x
中图分类号
R74 [神经病学与精神病学];
学科分类号
100204 [神经病学];
摘要
Objective: The present study evaluated inhaled loxapine for the acute treatment of agitation in patients with bipolar I disorder. Methods: A Phase 3, randomized, double blind, placebo-controlled, parallel group inpatient study was performed at 17 psychiatric research facilities. Agitated patients (N = 314) with bipolar I disorder (manic or mixed episodes) were randomized (1:1:1) to inhaled loxapine 5 mg or 10 mg, or inhaled placebo using the Staccato(R) system. Following baseline assessments, patients received Dose 1 and were evaluated for 24 hours. If required, up to two additional doses of study drug and/or lorazepam rescue medication were given. The primary efficacy endpoint was change from baseline in the Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) score two hours after Dose 1. The key secondary endpoint was the Clinical Global Impression-Improvement score at two hours after Dose 1. Additional endpoints included the changes from baseline in the PANSS-EC from 10 min through 24 hours after Dose 1. Safety was assessed by adverse events, vital signs, physical examinations, and laboratory tests. Results: For the primary and key secondary endpoints, both doses of inhaled loxapine significantly reduced agitation compared with placebo. Reduced agitation, as reflected in PANSS-EC score, was evident 10 min after Dose 1 with both doses. Inhaled loxapine was well tolerated, and the most common adverse events were known effects of loxapine or minor oral effects common with inhaled medications (dysgeusia was reported in 17% of patients receiving active drug versus 6% receiving placebo). Conclusions: Inhaled loxapine provided a rapid, non-injection, well-tolerated acute treatment for agitation in patients with bipolar I disorder.
引用
收藏
页码:31 / 40
页数:10
相关论文
共 32 条
[1]
Alderfer BS, 2003, J CLIN PSYCHIAT, V64, P3
[2]
Use of restraints and pharmacotherapy in academic psychiatric emergency services [J].
Allen, MH ;
Currier, GW .
GENERAL HOSPITAL PSYCHIATRY, 2004, 26 (01) :42-49
[3]
Allen MH, 2001, POSTGRAD MED, V110, P1
[4]
Efficacy and Safety of Loxapine for Inhalation in the Treatment of Agitation in Patients With Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial [J].
Allen, Michael H. ;
Feifel, David ;
Lesem, Michael D. ;
Zimbroff, Daniel L. ;
Ross, Ruth ;
Munzar, Patrik ;
Spyker, Daniel A. ;
Cassella, James V. .
JOURNAL OF CLINICAL PSYCHIATRY, 2011, 72 (10) :1313-1321
[5]
Pharmacological management of acute agitation [J].
Battaglia, J .
DRUGS, 2005, 65 (09) :1207-1222
[6]
Calming versus sedative effects of intramuscular olanzapine in agitated patients [J].
Battaglia, J ;
Lindborg, SR ;
Alaka, K ;
Meehan, K ;
Wright, P .
AMERICAN JOURNAL OF EMERGENCY MEDICINE, 2003, 21 (03) :192-198
[7]
Bourdinaud V, 2003, ENCEPHALE, V29, P89
[8]
A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia [J].
Breier, A ;
Meehan, K ;
Birkett, M ;
David, S ;
Ferchland, I ;
Sutton, V ;
Taylor, CC ;
Palmer, R ;
Dossenbach, M ;
Kiesler, G ;
Brook, S ;
Wright, P .
ARCHIVES OF GENERAL PSYCHIATRY, 2002, 59 (05) :441-448
[9]
Buckley PF, 1999, J CLIN PSYCHIAT, V60, P52
[10]
Loxapine for schizophrenia [J].
Chakrabarti, A. ;
Bagnall, A. ;
Chue, P. ;
Fenton, M. ;
Palaniswamy, V ;
Wong, W. ;
Xia, J. .
COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2007, (04)